Glial fibrillary acidic protein (GFAP), a proxy of astrocyte reactivity, has been proposed as
biomarker of Alzheimer's disease. However, there is limited information about the correlation …

Blood biomarkers have been considered tools for the diagnosis, prognosis, and monitoring
of Alzheimer's disease (AD). Although amyloid-β peptide (Aβ) and tau are primarily blood …

Although recent clinical trials targeting amyloid-β in Alzheimer's disease have shown
promising results, there is increasing evidence suggesting that understanding alternative …

Background Glial fibrillary acidic protein (GFAP) is a promising candidate blood‐based
biomarker for Alzheimer's disease (AD) diagnosis and prognostication. The timing of its …

Although recent clinical trials targeting amyloid-β (Aβ) in Alzheimer's disease (AD) have
shown promising results, there is increasing evidence suggesting that understanding …

Background Plasma glial fibrillary acidic protein (GFAP) has emerged as a promising
biomarker in neurological disorders, but further evidence is required in relation to its …

Background Glial fibrillary acidic protein (GFAP) is an astrocytic marker that has been
recently associated with fluid and imaging biomarkers of amyloid and tau pathologies in the …

Glial fibrillary acidic protein (GFAP), an astrocytic cytoskeletal protein, can be measured in
blood samples, and has been associated with Alzheimer's disease (AD). However, plasma …

Introduction There is a tremendous need for identifying reliable blood-based biomarkers for
Alzheimer's disease (AD) that are tied to the biological ATN (amyloid, tau and …

Introduction Plasma glial fibrillary acidic protein (GFAP) is a marker of astroglial activation
and astrocytosis. We assessed the ability of plasma GFAP to detect Alzheimer's disease …